Data / Drug companies / MSN Laboratories Private Limited
MSN Laboratories Private Limited: 24 products in the FDA NDC directory, labeler code 69539
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
MSN Laboratories Private Limited (labeler code 69539) lists 24 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 24 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 16, 2024.
The request: Watch MSN Laboratories Private Limited (FDA labeler code 69539): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 69539
- Products in commercial distribution
- 24
- Packages
- 42
- Finished drugs by generic name
- 7
- Prescription products
- 24
- Over the counter products
- 0
- Controlled substance products
- Schedule V 4
- Flagged as original packager
- 24 of 24 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- April 24, 2019
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 24 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 24 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Deferasirox | 6 | 21 |
| Asenapine maleate | 5 | 3 |
| Lacosamide | 4 | 57 |
| Teriflunomide | 4 | 17 |
| Dimethyl fumarate | 3 | 20 |
| Azacitidine | 1 | 20 |
| Oseltamivir phosphate | 1 | 37 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 8 | 33.3% |
| Tablet, film coated | 8 | 33.3% |
| Tablet, for suspension | 3 | 12.5% |
| Capsule, delayed release | 2 | 8.3% |
| Kit | 1 | 4.2% |
| Injection, powder, lyophilized, for solution | 1 | 4.2% |
| Capsule | 1 | 4.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Iron Chelator | 6 |
| Atypical Antipsychotic | 5 |
| Pyrimidine Synthesis Inhibitor | 4 |
| Nucleoside Metabolic Inhibitor | 1 |
| Neuraminidase Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Azacitidine | 69539-112 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 16, 2024 |
| Lacosamide | 69539-028 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Lacosamide | 69539-027 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Lacosamide | 69539-026 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Lacosamide | 69539-025 | Tablet, film coated | Generic drugs (ANDA) | March 19, 2022 |
| Asenapine | 69539-245 | Tablet | Generic drugs (ANDA) | August 27, 2021 |
| Asenapine | 69539-060 | Tablet | Generic drugs (ANDA) | August 27, 2021 |
| Asenapine | 69539-059 | Tablet | Generic drugs (ANDA) | August 27, 2021 |
| Asenapine | 69539-058 | Tablet | Generic drugs (ANDA) | August 27, 2021 |
| Asenapine | 69539-057 | Tablet | Generic drugs (ANDA) | August 27, 2021 |
| Dimethyl Fumarate | 69539-240 | Kit | Generic drugs (ANDA) | May 20, 2021 |
| Dimethyl Fumarate | 69539-043 | Capsule, delayed release | Generic drugs (ANDA) | September 28, 2020 |
| Dimethyl Fumarate | 69539-042 | Capsule, delayed release | Generic drugs (ANDA) | September 28, 2020 |
| Deferasirox | 69539-074 | Tablet | Generic drugs (ANDA) | June 16, 2020 |
| Oseltamivir phosphate | 69539-110 | Capsule | Generic drugs (ANDA) | May 22, 2020 |
| Deferasirox | 69539-075 | Tablet | Generic drugs (ANDA) | November 20, 2019 |
| Deferasirox | 69539-073 | Tablet | Generic drugs (ANDA) | November 20, 2019 |
| Deferasirox | 69539-023 | Tablet, for suspension | Generic drugs (ANDA) | November 20, 2019 |
| Deferasirox | 69539-022 | Tablet, for suspension | Generic drugs (ANDA) | November 20, 2019 |
| Deferasirox | 69539-021 | Tablet, for suspension | Generic drugs (ANDA) | November 20, 2019 |
| Teriflunomide | 69539-316 | Tablet, film coated | Generic drugs (ANDA) | April 24, 2019 |
| Teriflunomide | 69539-315 | Tablet, film coated | Generic drugs (ANDA) | April 24, 2019 |
| Teriflunomide | 69539-033 | Tablet, film coated | Generic drugs (ANDA) | April 24, 2019 |
| Teriflunomide | 69539-032 | Tablet, film coated | Generic drugs (ANDA) | April 24, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.